News ArticleGlaxoSmithKline Pharmaceuticals Ltd Reports Rs.117991 Lakh Revenue in Q2 FY2026, Appoints Sandeep Seth and New Statutory Auditor
Board approves unaudited standalone financials for Q2 and H1 FY2026, appoints Head - Ethics & Compliance and Walker Chandiok & Co LLP as statutory auditors for five years starting FY2027-28
GlaxoSmithKline Pharmaceuticals Limited announced its unaudited standalone financial results for the quarter and half year ended 30th September 2026. The company reported revenue from operations of Rs. 117991 lakh for Q2 and Rs. 210433 lakh for H1 FY2026. In addition, the board approved the appointment of Mr. Sandeep Seth as Head - Ethics & Compliance and M/s Walker Chandiok & Co LLP as statutory auditors for five years starting FY2027-28, subject to member approval.
GlaxoSmithKline Pharmaceuticals Limited
Financial Results
GlaxoSmithKline Pharmaceuticals Limited announced its unaudited standalone financial results for the quarter and half year ended 30th September 2026, reporting revenue from operations of Rs. 117991 lakh in Q2 FY2026 and Rs. 210433 lakh in the first half of FY2026. Alongside, the company appointed Mr. Sandeep Seth as Head - Ethics & Compliance and approved M/s Walker Chandiok & Co LLP as statutory auditors for five years starting FY2027-28, pending shareholder approval.
The company's total income for Q2 FY2026 was Rs. 125268 lakh, including other income of Rs. 7277 lakh. Total expenses for the quarter stood at Rs. 79510 lakh, resulting in a profit before tax of Rs. 45758 lakh. For the half year ended 30th September 2026, total income was Rs. 223873 lakh with a profit before tax of Rs. 79556 lakh.
Mr. Sandeep Seth was appointed as Head - Ethics & Compliance effective 3rd November 2026. Seth is a qualified lawyer and certified compliance professional with over 20 years of experience in ethics and compliance across pharmaceutical, healthcare, and insurance sectors.
The board also approved the appointment of M/s Walker Chandiok & Co LLP as statutory auditors for a five-year term from financial year 2027-28 to 2031-32, subject to member approval at the forthcoming Annual General Meeting. The firm is a reputed chartered accountancy firm with a history since 1935 and significant experience auditing large listed companies in India.
Highlights
- Q2 FY2026 standalone revenue from operations: Rs. 117991 lakh
- Half year FY2026 revenue from operations: Rs. 210433 lakh
- Profit before tax for Q2 FY2026: Rs. 45758 lakh
- Mr. Sandeep Seth appointed as Head - Ethics & Compliance effective 3 November 2026
- Appointment of M/s Walker Chandiok & Co LLP as statutory auditors for five years starting FY2027-28, subject to member approval
Key Data Snapshot
What happened
- GlaxoSmithKline Pharmaceuticals Limited reported unaudited standalone financial results for Q2 and H1 FY2026.
- Revenue from operations was Rs. 117991 lakh for Q2 and Rs. 210433 lakh for the half year.
- Mr. Sandeep Seth was appointed as Head - Ethics & Compliance effective 3rd November 2026.
- M/s Walker Chandiok & Co LLP was approved as the new statutory auditor for a five-year term from FY2027-28 to FY2031-32, pending shareholder approval.
Key details
- Total income for Q2 FY2026 including other income was Rs. 125268 lakh.
- Q2 total expenses were Rs. 79510 lakh, yielding a profit before tax of Rs. 45758 lakh.
- Sandeep Seth has over 20 years of compliance experience and is a qualified lawyer and certified compliance professional.
- Walker Chandiok & Co LLP was established in 1935 and is registered with ICAI and PCAOB, auditing many top listed entities in India.
Background and context
- This announcement was made as part of the Board meeting held on 3rd November 2026.
- The financial results are unaudited but have been subjected to limited review by auditors.
- Appointment of statutory auditors is subject to approval by the company’s members at the forthcoming Annual General Meeting.
- The company’s paid-up equity share capital is Rs. 16941 lakh with a face value of Rs. 10 per share.
Highlights
- Q2 FY2026 standalone revenue from operations: Rs. 117991 lakh
- Half year FY2026 revenue from operations: Rs. 210433 lakh
- Profit before tax for Q2 FY2026: Rs. 45758 lakh
- Mr. Sandeep Seth appointed as Head - Ethics & Compliance effective 3 November 2026
- Appointment of M/s Walker Chandiok & Co LLP as statutory auditors for five years starting FY2027-28, subject to member approval
Disclosures
- SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Biocon Limited Reports Rs. 1,439 Million Profit for H1 FY2026-27; Appoints Mukesh Rathi as New CTO from January 2027
Biocon Limited declared its unaudited standalone financial results for the quarter and half-year ended September 30, 2026, reporting a profit of Rs. 1,439 million for the half-year. Alongside financial disclosure, the company announced a change in its senior management with the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as the new CTO starting January 1, 2027.
Read Full Story
Zydus Lifesciences Posts ₹10,541 Million Net Profit for Half Year Ending September 30, 2026
Zydus Lifesciences Limited announced its unaudited standalone financial results for the quarter and half year ended September 30, 2026, recording a net profit of ₹7,145 million for Q2 and ₹10,541 million for the half year.
Read Full Story
Fractal Analytics Limited Reports Unaudited Q2 and H1 2026 Financial Results and Approves Winding Up of Analytics Vidhya Inc
Fractal Analytics Limited announced its unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2026. Additionally, the company's Board has approved winding up its step-down subsidiary Analytics Vidhya Inc., aiming to simplify group corporate structure and enhance operational efficiency without affecting ongoing business activities.
Read Full Story
